Will Morgan Stanley's Q1 2026 Investment Banking revenue grow at least 20% year over year?
Current Prediction
Why This Question Matters
The Q1 2026 Investment Banking growth rate is the single most important validation of Pick's 'third inning' framing. A 20%+ growth result supports the narrative; sub-20% suggests mid-cycle normalization and triggers multiple compression risk even without a fundamental miss.
Prediction Distribution
Individual Predictions(9 runs)
Q4 2025 delivered 47% YoY IB growth with management explicitly citing healthy global diversified pipelines. Q1 2025's $1.6B baseline is relatively weak, making 20% YoY ($1.92B) achievable. Pipeline momentum from Q4 typically carries into Q1 via debt underwriting and M&A close timing. Headwinds: Pick's cautionary language, lumpy M&A timing, and the possibility that capital markets activity slowed in February-March. Net lean YES.
The 20% threshold is meaningful but achievable given Q4 acceleration. The insider selling cluster in January is a weak counter-signal for cycle peak awareness, but Q1 2026 is too early for that to show in numbers. The cyclical pattern typically shows Q1 recovery off Q4 momentum. However, the 'third inning' framing may be optimistic and normalization is possible. Probability around 58-60%.
20% YoY growth is the base case given the Q4 trajectory and weak Q1 2025 comp. MS has been consistently beating expectations and the pipeline color is strong. The main downside risk is equity underwriting volatility — IPO activity can pause on any macro noise. Advisory is typically more lumpy. Lean YES at around 60%.
20% is a high bar but not unreasonable given the trajectory. Management's healthy pipeline commentary supports continuation. However, Q1 is often seasonally softer for M&A close activity and debt underwriting can swing meaningfully. Close to coin flip with slight lean YES.
Q4 momentum + weak Q1 comp + healthy pipeline = lean YES. The insider selling cluster is a peripheral concern. Probability around 60%.
This is genuinely close. The bullish case is strong but 20% is a specific threshold and M&A timing is lumpy. Q1 2025 had $1.6B — beating by 20% requires ~$1.92B which is below Q4 2025 ($2.4B). The deceleration from Q4 is expected but magnitude is uncertain.
Strong Q4 momentum and weak Q1 2025 baseline favor YES. Pipeline commentary is constructive. Lean positive around 60%.
The trajectory supports YES but with meaningful uncertainty given quarterly lumpiness and the specific 20% threshold. 58% reflects a balanced view.
Base case is around 20% growth given the Q4 setup. The threshold is exactly at the expected value, creating genuine coin-flip uncertainty on the exact magnitude. Slight lean YES.
Resolution Criteria
Resolves YES if Morgan Stanley reports Q1 2026 Investment Banking revenue (as disclosed in the Q1 2026 earnings release or 10-Q) at least 20% above Q1 2025 IB revenue. Resolves NO otherwise.
Resolution Source
Morgan Stanley Q1 2026 earnings press release and 10-Q
Source Trigger
Investment Banking Revenue YoY Growth — sub-10% YoY on Q1 2026 or pipeline commentary shift from 'healthy' to 'mixed' would signal cycle peak interpretation
Full multi-lens equity analysis